share_log

TECON BIOLOGYLTD (SZSE:002100 Investor Three-year Losses Grow to 11% as the Stock Sheds CN¥478m This Past Week

TECON BIOLOGYLTD (SZSE:002100 Investor Three-year Losses Grow to 11% as the Stock Sheds CN¥478m This Past Week

TECON生物技术股份有限公司(SZSE:002100)投资者三年损失增至11%,本周该股票脱落了4.78亿元人民币。
Simply Wall St ·  06/10 18:38

It can certainly be frustrating when a stock does not perform as hoped. But it can difficult to make money in a declining market. While the TECON BIOLOGY Co.LTD (SZSE:002100) share price is down 13% in the last three years, the total return to shareholders (which includes dividends) was -11%. That's better than the market which declined 23% over the last three years.

当一只股票的走势不符合预期时,确实会让人感到沮丧。但在一个下跌的市场里赚钱可能并不容易。尽管天康生物股份有限公司(SZSE:002100)的股价在过去三年中下跌了13%,但股东的总回报(其中包括股息)为-11%。这比市场的跌幅23%好一些。

If the past week is anything to go by, investor sentiment for TECON BIOLOGYLTD isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

如果过去一周是真的,那么天康生物股份有限公司的投资者情绪并不是很乐观,因此让我们来看看基本面和股价之间是否存在不匹配问题。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

虽然一些人仍然在教授高效市场假说,但已经证明市场是过度反应的动态系统,投资者不总是理性的。一种有缺陷但合理的评估公司情绪变化的方法是比较每股收益 (EPS) 与股价。

TECON BIOLOGYLTD saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.

天康生物股份有限公司的股价在过去三年中下跌,其每股收益也下降至亏损。由于该公司转入了亏损地带,因此很难将每股收益的变化与股价的变化进行比较。然而,在这种情况下,我们可以肯定地说,股价应该会下跌。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下面的图片中查看每股收益如何随时间变化(单击图表以查看确切的价值)。

earnings-per-share-growth
SZSE:002100 Earnings Per Share Growth June 10th 2024
SZSE:002100每股收益增长2024年6月10日

It might be well worthwhile taking a look at our free report on TECON BIOLOGYLTD's earnings, revenue and cash flow.

我们已经介绍了天康生物股份有限公司的股价表现,但我们也应该提到其股东总回报(TSR)。 TSR试图捕捉股息的价值(就像它们已被再投资一样),以及公司向股东提供的任何剥离或折价的资本增发。天康生物股份有限公司的TSR在过去的三年中损失了11%。尽管它支付了股息,但它的股价回报并不那么糟糕。

What About The Total Shareholder Return (TSR)?

那么,股东总回报(TSR)呢?

We've already covered TECON BIOLOGYLTD's share price action, but we should also mention its total shareholder return (TSR). The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. TECON BIOLOGYLTD's TSR of was a loss of 11% for the 3 years. That wasn't as bad as its share price return, because it has paid dividends.

可能值得一看的是我们关于天康生物股份有限公司收益、营业收入和现金流的免费报告。我们已经介绍了天康生物股份有限公司的股价表现,但我们也应该提到其股东总回报(TSR)。 TSR试图捕捉股息的价值(就像它们已被再投资一样),以及公司向股东提供的任何剥离或折价的资本增发。天康生物股份有限公司的TSR在过去的三年中损失了11%。尽管它支付了股息,但它的股价回报并不那么糟糕。

A Different Perspective

不同的观点

Although it hurts that TECON BIOLOGYLTD returned a loss of 0.7% in the last twelve months, the broader market was actually worse, returning a loss of 12%. Longer term investors wouldn't be so upset, since they would have made 1.3%, each year, over five years. In the best case scenario the last year is just a temporary blip on the journey to a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for TECON BIOLOGYLTD that you should be aware of.

虽然天康生物股份有限公司在过去的十二个月中损失了0.7%,但更广泛的市场实际上表现更差,损失了12%。从长期来看,投资者不会那么沮丧,因为他们每年可以获得1.3%的回报,持有五年的话。最好的情况是过去一年只是征程中的短暂波动。我认为长期股价变化是企业绩效的一种代理,但要真正获得洞察力,我们还需要考虑其他信息。例如,我们已经发现天康生物股份有限公司存在1个警示信号,您应该注意。

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

对于那些喜欢寻找获胜投资的人来说,最近有内部购买的低估公司免费列表可能是一个很好的选择。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发